Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02061865
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01997164
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01979016
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 253
- Registration Number
- NCT01963598
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2733
- Registration Number
- NCT01949311
- Locations
- 🇵🇱
Regeneron Study Site 5, Warszawa, Mazowieckie, Poland
🇪🇸Regeneron Study Site 4, Barcelona, Spain
🇬🇧Regeneron Study Site 1, London, United Kingdom
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01933763
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 803
- Registration Number
- NCT01926782
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2014-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01922661
Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT01910220
Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers
- First Posted Date
- 2013-07-09
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT01893528
© Copyright 2024. All Rights Reserved by MedPath